911469-22-2

Upstream product

• 846049-64-7 2-[(4-bromo-phenyl)-piperidin-4-ylidene-methyl]-5-fluoro-6-trifluoromethyl-1H-benzoimidazole 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 16532-79-9 4-Bromophenylacetonitrile 
• 846049-68-1 4-[(4-bromo-phenyl)-(5-fluoro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-50-1 4-[(4-bromo-phenyl)-cyano-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-52-3 4-[1-(4-bromo-phenyl)-2-oxo-ethylidene]-piperidine-1-carboxylic acid tert-butyl ester 
• 903899-11-6 2-[(4-bromo-phenyl)-(1-cyclopropylmethyl-piperidin-4-ylidene)-methyl]-5-fluoro-6-trifluoromethyl-1H-benzoimidazole 
• 73183-34-3 bis(pinacol)diborane 

Relevant academic research and scientific papers

Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists

Biaryl urea lead compound 1 was discovered earlier in our MCH antagonist program. Novel benzimidazole analogues with increased chemical stability, devoid of the potential carcinogenic liability associated with a biarylamine moiety, were synthesized and evaluated to be potent MCH R1 antagonists. Two compounds in this series have demonstrated in vivo efficacy in a rodent obesity model.